Effects of Ad5FGF-4 in Patients With Angina Henry, Timothy D., MD, FACC; Grines, Cindy L., MD, FACC; Watkins, Matthew W., MD, FACC ...
Journal of the American College of Cardiology,
09/2007, Letnik:
50, Številka:
11
Journal Article
Recenzirano
Odprti dostop
Effects of Ad5FGF-4 in Patients With Angina: An Analysis of Pooled Data From the AGENT-3 and AGENT-4 Trials Timothy D. Henry, Cindy L. Grines, Matthew W. Watkins, Nabil Dib, Gerald Barbeau, Randall ...Moreadith, Tony Andrasfay, Robert L. Engler Ad5FGF-4 (Generx, Berlex Biosciences, Richmond, California) is a potential angiogenic therapeutic that was tested in 2 trials. Both were halted for lack of efficacy after an interim analysis. An analysis using pooled data from the 2 nearly identical trials was performed to investigate possible treatment effects. The effect of placebo was large and not different than active treatment in men, but the placebo effect in women was negligible. We found a significant, female gender-specific beneficial effect of Ad5FGF-4 on total exercise treadmill test time, time to 1 mm ST-segment depression, time to angina, and Canadian Cardiovascular Society class.
Abstract Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However, many patients and healthcare providers prematurely ...discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis, myocardial infarction, and death. This advisory stresses the importance of 12 months of dual antiplatelet therapy after placement of a drug-eluting stent and educating the patient and healthcare providers about hazards of premature discontinuation. It also recommends postponing elective surgery for 1 year, and if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in high-risk patients with drug-eluting stents.
The Year in Interventional Cardiology Dixon, Simon R., MBChB, FRACP, FACC; Grines, Cindy L., MD, FACC; O'Neill, William W., MD, FACC
Journal of the American College of Cardiology,
06/2008, Letnik:
51, Številka:
24
Journal Article
Recenzirano
Odprti dostop
Patients treated with early abciximab showed benefits in pre-PCI TIMI flow grade 3 (24% vs. 10%; p = 0.01), better frame counts, and blush scores. ...post-PCI ST-segment resolution (50% vs. 35% of ...patients; p = 0.3) and 1-month improvement in ejection fraction (EF) (8% vs. 6%; p = 0.2) favored the early abciximab group. Table 5 Trials Evaluating Use of Sodium Bicarbonate Infusion for Prevention of Contrast-Induced Nephropathy in 2007 CHF = congestive heart failure; CIN = contrast-induced nephropathy; ClCr = creatinine clearance; eGFR = estimated glomerular filtration rate; NAC = N-acetylcysteine; REMEDIAL = Renal Insufficiency Following Contrast Media Administration Trial; RENO = Registry Novoste; sCr = serum creatinine.
The Year in Interventional Cardiology Dixon, Simon R., MBChB, FRACP, FACC; Grines, Cindy L., MD, FACC; O’Neill, William W., MD, FACC
Journal of the American College of Cardiology,
07/2007, Letnik:
50, Številka:
3
Journal Article
Recenzirano
Odprti dostop
...primary PCI was associated with shorter hospital stay and less reinfarction. ...both randomized trials and large registries continue to show the benefit of primary PCI over thrombolysis, and call ...into question whether primary PCI should be preferred over thrombolysis even when the delay to the catheterization laboratory exceeds 120 min. The primary end point of death, heart failure, or shock at 90 days also was higher in the facilitated arm (19% vs. 13%, p = 0.0045). ...patients in the facilitated PCI arm had more strokes (1.8% vs. 0%, p < 0.0001), reinfarction (6% vs. 4%, p = 0.027), repeat target vessel revascularizations (TVRs) (7% vs. 3%, p = 0.0041), and bleeding complications.
PDF
